$36M Injection Fuels Remepy’s AI-Powered Drug Pipeline Expansion

Remepy has secured $36 million in Series A funding to expand its pipeline of Hybrid Drugs, treatments that combine prescription medications with AI-driven therapeutic apps.

The round was led by O.G. Venture Partners and M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, with existing and new investors also participating.

The funding will be used to advance Remepy's pipeline and platform, expand pharma partnerships, and fund global Phase III development of Hybridopa, its lead program for Parkinson's disease.

Hybridopa has shown encouraging Phase IIa results, with improvement in both motor and non-motor symptoms in Parkinson's patients. The trial is expected to begin in the fourth quarter of 2026.